Scientific publications - Median Technologies

Hubert Beaumont [1], Antoine Iannessi [2], Anne-Sophie Bertrand [3], Jean Michel Cucchi [3], Olivier Lucidarme [4] - Affiliations: [1] Median Technologies, Valbonne , France. [2] Centre Antoine Lacassagne, Nice, France. [3] Centre Hospitalier Princesse Grâce, Monaco. [4] Hopital La Pitié Salpêtrière, Paris, France.

This scientific paper published in European Radiology addresses the generalizability of classification models performances in improving the reliability of radiomic features using harmonized data. The work was conducted on diseased/non-diseased liver images and evaluated two different harmonization approaches. This paper is a result of a collaboration between Centre Hospitalier Princesse Grâce, Monaco, AP-HP La Pitié Salpêtrière, Paris and Median Technologies.

Elton Rexhepaj [1], Corinne Ramos [1], Yan Liu [1], Benoit Huet [1], Olivier Lucidarme [2], Nozha Boujemaa [1] – Affiliations: [1] Median Technologies, Valbonne, France - [2] Hôpital Universitaire Pitié-Salpêtrière-APHP, Paris, France

Poster presented at the Digital International Liver Congress – EASL – August 27-29, 2020

Hepatic fibrosis diagnosis is important for risk stratification, prognosis evaluation and monitoring of treatment response. Using computer tomography (CT) perfusion imaging and splenic radiomics, the objective of this study is to validate the use this non-invasive fibrosis scoring method to identify patients whose tumors are at high risk of recurrence after hepatic resection.

Hubert Beaumont [1], Antoine Iannessi [1], Jennifer Cillario [1], Yan Liu [1] – Affiliations: [1] Median Technologies, Valbonne, France

Poster presented at the ESMO Asia meeting – November 20-22, 2020

The poster presents results from a study dealing with inter-reader discrepancies in image-based oncology trials in BICR settings. Inter-reader discrepancy is a metric of choice for detecting quality issues in clinical trials. The study provides reference values metrics to monitor reader performance with double read plus adjudication in clinical trials using RECIST 1.1.

Yan Liu [1] [2] , Elton Rexhepaj [3] , Afef Baili Laya [3] , Corinne Ramos [3] , Hubert Beaumont [1] , Nozha Boujemaa [3] , Anthony Lockett [2] - Affiliations [1] Medical Affairs, Median Technologies, Valbonne, France, [2] Bioscience , King's College London, London, UK - [3] iBiopsy® Business Unit, Median Technologies, Valbonne, France

Poster presented at The Liver Meeting, organized by the American Association for the Study of Liver Diseases, Nov 13-16, 2020 – Virtual experience

Based on a meta-analysis, the poster analyses radiomics contribution to liver cancer recurrence prediction and shows how radiomics are approaching their limits for predicting disease outcome.  Imaging phenomics, an emerging technology implemented in Median’s iBiopsy® platform may provide the framework to explore new associations between phenotypes which are currently not feasible using traditional radiomic workflows.

Antoine Iannessi [1], Hubert Beaumont [1], Yan Liu [1], Anne Sophie Bertrand [2] - Affiliations: [1] Median Technologies, Valbonne, France, [2] Polyclinique Les Fleurs, 83190 Ollioules, France

Poster presented at the ESMO 2020 Virtual Congress | September 17, 2020 |Poster Display Session 1936P

For tumor response assessment in oncology trials with radiology, the baseline (BL) evaluation is critical as the selection of target lesions (TL) determines the quality of follow-up. The RECIST workgroup provided a method and recommendations for: 1) selecting TL and non-target lesions (NTL) for reporting disease evolution, 2) choosing up to 5 targets, with a maximum of two per organs. In the practice, the selection of TL is subjective; non-malignant (NM) lesions might be mistaken as TLs. The objectives of the study are 1) to analyze the impact of selecting non-malignant lesions as target lesions at baseline, and 2) to present recommendations to mitigate risks in clinical trials.